Key result
In patients with arrhythmogenic right ventricular cardiomyopathy and sustained ventricular tachycardia, the presence of an endocardial scar in the superior tricuspid valve predicted VT/VF recurrence (HR 3.596).
Why the study?
The substrate characteristics and ablation outcomes in ARVC patients with or without RV dysfunction were unclear.
Does the presence of right ventricular dysfunction and specific scar distribution predict ventricular tachycardia recurrence after catheter ablation in patients with ARVC?
Cohort (n=106)
Does the presence of right ventricular dysfunction and specific scar distribution predict ventricular tachycardia recurrence after catheter ablation in patients with ARVC?
Hazard Ratio: 3.596 (95% CI 1.412–9.16)
p-value: p=0.007
Larger abnormal RV substrates in ARVC with dysfunction may guide mapping; leaves open whether ablation outcomes differ by RV function.
Background The substrate and ablation outcome in arrhythmogenic right ventricular cardiomyopathy (ARVC) with or without right ventricular (RV) dysfunction is unclear. Objective We aimed to investigate ablation outcome and substrate in ARVC patients with or without RV dysfunction. Methods We retrospectively studied ARVC patients with (group 1) or without RV dysfunction (group 2) undergoing substrate mapping/ablation. Baseline characteristics and electrophysiological features were compared. The RV was divided into 7 prespecified segments. The scarred segment was defined as more than 50% of the area with bipolar scar. A multivariate regression analysis was performed to predict the risk of ventricular tachycardia (VT) recurrence. Results A total of 106 patients were enrolled (57 in group 1 and 49 in group 2). There were more men (73.7% vs 32.7%, P < .05) in group 1 than group 2. Group 1 patients demonstrated larger abnormal substrate in both the endocardium (13.4 ± 14.7 cm 2 vs 7.8 ± 5.4 cm 2 , P = .014) and in the epicardium (40.3 ± 27.7 cm 2 vs 14.2 ± 12.6 cm 2 , P = .002) and had more scar in the inferior portion/tricuspid valve (TV) than group 2 patients. Twenty-five patients had recurrences of VT/ventricular fibrillation. After multivariate analysis, the presence of a superior TV scar in the endocardium predicted the recurrence in patients with sustained VT. Conclusion The presence of RV dysfunction was associated with a larger abnormal substrate in the endocardium and epicardium of the RV. A scar involving the inferior portion and TV is associated with RV dysfunction. Scarring in the superior TV of the endocardium can predict recurrence despite catheter ablation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) conducted a cohort in Arrhythmogenic right ventricular cardiomyopathy (n=106). Endocardial scar in the superior tricuspid valve vs. Absence of endocardial scar in the superior tricuspid valve was evaluated on Recurrence of sustained ventricular tachycardia or ventricular fibrillation (HR 3.596, 95% CI 1.412-9.160, p=0.007). In patients with arrhythmogenic right ventricular cardiomyopathy and sustained ventricular tachycardia, the presence of an endocardial scar in the superior tricuspid valve predicted VT/VF recurrence (HR 3.596).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: